Teladoc, Inc. provides telehealth services worldwide. It offers a portfolio of services and solutions covering 450 medical subspecialties, such as flu and upper respiratory infections, cancer, and congestive heart failure. The company provides its services through mobile devices, the Internet, video, and phone. It serves employers of Fortune 1000 companies, health plans, health systems, and other entities. Teladoc, Inc. was founded in 2002 and is headquartered in Purchase, New York.
Industry, Sector and Symbol
Stock Exchange NYSE
Industry Offices & clinics of medical doctors
Sub-IndustryN/A
SectorMedical
SymbolNYSE:TDOC
CUSIPN/A
Phone203-635-2002
Debt
Debt-to-Equity Ratio0.38
Current Ratio4.15
Quick Ratio4.15
Price-To-Earnings
Trailing P/E Ratio-41.55
Forward P/E Ratio-47.60
P/E GrowthN/A
Sales & Book Value
Annual Sales$233.28 million
Price / Sales18.32
Cash FlowN/A
Price / CashN/A
Book Value$9.80 per share
Price / Book6.99
Profitability
EPS (Most Recent Fiscal Year)($1.65)
Net Income$-106,780,000.00
Net Margins-41.06%
Return on Equity-20.40%
Return on Assets-12.48%
Miscellaneous
Employees1,231
Outstanding Shares62,330,000
Market Cap$4,388.35
Teladoc (NYSE:TDOC) Frequently Asked Questions
What is Teladoc's stock symbol?
Teladoc trades on the New York Stock Exchange (NYSE) under the ticker symbol "TDOC."
How were Teladoc's earnings last quarter?
Teladoc Inc (NYSE:TDOC) issued its earnings results on Tuesday, May, 1st. The health services provider reported ($0.39) earnings per share for the quarter, beating analysts' consensus estimates of ($0.43) by $0.04. The health services provider had revenue of $89.64 million for the quarter, compared to the consensus estimate of $86.77 million. Teladoc had a negative return on equity of 20.40% and a negative net margin of 41.06%. The firm's quarterly revenue was up 109.0% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.30) EPS. View Teladoc's Earnings History.
When is Teladoc's next earnings date?
What guidance has Teladoc issued on next quarter's earnings?
Teladoc updated its FY18 earnings guidance on Tuesday, May, 1st. The company provided earnings per share guidance of ($1.41-1.36) for the period, compared to the Thomson Reuters consensus earnings per share estimate of ($1.35). The company issued revenue guidance of $350-360 million, compared to the consensus revenue estimate of $356.28 million.Teladoc also updated its Q2 guidance to ($0.37-0.35) EPS.
What price target have analysts set for TDOC?
18 brokers have issued 12-month price objectives for Teladoc's shares. Their forecasts range from $39.00 to $80.00. On average, they anticipate Teladoc's share price to reach $55.50 in the next twelve months. This suggests that the stock has a possible downside of 19.0%. View Analyst Ratings for Teladoc.
What is the consensus analysts' recommendation for Teladoc?
18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Teladoc in the last year. There are currently 4 hold ratings and 14 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
What are Wall Street analysts saying about Teladoc stock?
Here are some recent quotes from research analysts about Teladoc stock:
- 1. Cantor Fitzgerald analysts commented, "4Q17 in line or slightly better than expected. Revenue was $77 million vs. our estimate and FactSet of consensus of $76 million. Visits grew 49%. PMPM was $0.95 vs. $0.91 in 3Q17. Gross margin declined y/y given the expected revenue shift. TDOC reported positive adjusted EBITDA of $2.4M vs FactSet $2.5M. GAAP EPS included several non-recurring/non-cash items. Overall, we believe that TDOC had a strong quarter." (2/27/2018)
- 2. According to Zacks Investment Research, "The stock of Teladoc has outperformed the industry year to date. The company is witnessing steady business growth with insurers and customers increasingly embracing telehealth. It’s organic growth initiative remains on track. With a number of acquisitions completed since its inception, the company has expanded its distribution capabilities and broadened its service offering. Also the company boasts an impressive clientele. The company has also provided strong guidance for 2017. The company has incurred significant losses in each period since its inception in 2002. Teladoc has been unable to generate cash from operations and we have doubts over its ability to do so in the coming quarters. Its high debt level has caused a spike in interest expense which has dented its operating margins." (10/18/2017)
Who are some of Teladoc's key competitors?
Some companies that are related to Teladoc include UCB S A/ADR (UCBJY), Quest Diagnostics (DGX), ResMed (RMD), Smith & Nephew (SNN), Cardinal Health (CAH), UCB (UCBJF), Incyte (INCY), GRIFOLS S A/S (GRFS), H. Lundbeck A/S- (HLUYY), IPSEN S A/S (IPSEY), OLYMPUS Corp/S (OCPNY), Novozymes A/S (NVZMF), Merck KGaA (MKGAF), GENMAB A/S/S (GMXAY) and Ramsay Health Care Limited Fully Paid Ord. Shrs (RHC).
Who are Teladoc's key executives?
Teladoc's management team includes the folowing people:
- Mr. Jason Gorevic, CEO & Director (Age 46)
- Mr. Peter A. McClennen, Pres (Age 49)
- Mr. Mark J. Hirschhorn, Chief Financial Officer, Chief Operating Officer and Exec. VP (Age 53)
- Mr. Adam C. Vandervoort, Chief Legal Officer and Sec. (Age 43)
- Mr. Michael King, Chief Sales Officer (Age 55)
When did Teladoc IPO?
(TDOC) raised $112 million in an initial public offering on Wednesday, July 1st 2015. The company issued 7,000,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan and Deutsche Bank Securities acted as the underwriters for the IPO and William Blair, Wells Fargo Securities and SunTrust Robinson Humphrey were co-managers.
Has Teladoc been receiving favorable news coverage?
News headlines about TDOC stock have been trending somewhat positive this week, Accern reports. The research group ranks the sentiment of press coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Teladoc earned a media sentiment score of 0.04 on Accern's scale. They also assigned news stories about the health services provider an impact score of 47.00 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company's share price in the immediate future.
Who are Teladoc's major shareholders?
Teladoc's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Riverbridge Partners LLC (1.40%), Summit Partners L P (1.04%), Baillie Gifford & Co. (0.98%), Peregrine Capital Management LLC (0.60%), Fred Alger Management Inc. (0.12%) and Handelsbanken Fonder AB (0.07%). Company insiders that own Teladoc stock include Adam C Vandervoort, Andrew Turitz, James K Outland, Jason N Gorevic, Lewis Levy, Lp Chp III, Mark Hirschhorn, Michael Goldstein, Michael H King, Peter A Mcclennen and Trident Capital Fund Vi Lp. View Institutional Ownership Trends for Teladoc.
Which institutional investors are selling Teladoc stock?
TDOC stock was sold by a variety of institutional investors in the last quarter, including Peregrine Capital Management LLC and Riverbridge Partners LLC. Company insiders that have sold Teladoc company stock in the last year include Adam C Vandervoort, Andrew Turitz, Jason N Gorevic, Lewis Levy, Mark Hirschhorn, Michael Goldstein and Peter A Mcclennen. View Insider Buying and Selling for Teladoc.
Which institutional investors are buying Teladoc stock?
TDOC stock was acquired by a variety of institutional investors in the last quarter, including Summit Partners L P, Baillie Gifford & Co., Fred Alger Management Inc., Handelsbanken Fonder AB, Calamos Advisors LLC, Daiwa SB Investments Ltd., Benjamin F. Edwards & Company Inc. and Garner Asset Management Corp. View Insider Buying and Selling for Teladoc.
How do I buy shares of Teladoc?
Shares of TDOC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Teladoc's stock price today?
One share of TDOC stock can currently be purchased for approximately $68.55.
How big of a company is Teladoc?
Teladoc has a market capitalization of $4.39 billion and generates $233.28 million in revenue each year. The health services provider earns $-106,780,000.00 in net income (profit) each year or ($1.65) on an earnings per share basis. Teladoc employs 1,231 workers across the globe.
How can I contact Teladoc?
Teladoc's mailing address is 2 MANHATTANVILLE ROAD SUITE 203, PURCHASE NY, 10577. The health services provider can be reached via phone at 203-635-2002 or via email at [email protected]
MarketBeat Community Rating for Teladoc (NYSE TDOC)
MarketBeat's community ratings are surveys of what our community members think about Teladoc and other stocks. Vote "Outperform" if you believe TDOC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TDOC will underperform the S&P 500 over the long term. You may vote once every thirty days.
